Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ALDX | 8-K | bullish | 7/10 | Aldeyra Therapeutics announced its intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA's Office of Ne | Sep 29, 2026 |
| IMMX | 8-K | bullish | 7/10 | Immix Biopharma reported an interim update from its Phase 2 NEXICART-2 trial showing an 89% (40/45) complete response ra | Sep 29, 2026 |
| BYSI | 424B5 | bearish | 6/10 | BeyondSpring Inc. filed a 424B5 prospectus supplement to establish a new at-the-market (ATM) equity offering program for | Sep 29, 2026 |
| OKYO | 6-K | neutral | 3/10 | OKYO Pharma announced its participation and presentation at upcoming ophthalmic conferences (Eyecelerator, American Acad | Sep 29, 2026 |
| AZN | 6-K | bullish | 5/10 | AstraZeneca announced a $2 billion strategic equity investment in Summit Therapeutics, acquiring preferred stock convert | Sep 29, 2026 |
| PHAR | 6-K | bearish | 5/10 | Pharming Group N.V. announced the immediate departure of CEO Fabrice Chouraqui due to misalignment with the Board on str | Sep 29, 2026 |
| ALZN | 8-K | neutral | 3/10 | Alzamend Neuro filed an 8-K to disclose a presentation at the ISMRT Conference on September 29, 2026, by the principal i | Sep 29, 2026 |
| WLK | 8-K | bearish | 6/10 | Westlake announced the closure of its Cologne, Germany PVC plant (165,000 metric tons annual capacity) due to challengin | Sep 29, 2026 |
| HCM | 6-K | bullish | 7/10 | HUTCHMED announced that AstraZeneca has submitted a US NDA to the FDA for ORPATHYS (savolitinib) plus TAGRISSO (osimerti | Sep 29, 2026 |
| EVO | 6-K | neutral | 3/10 | Evotec announced that Chief Scientific Officer Dr. Cord Dohrmann will step down effective September 30, 2026, by mutual | Sep 29, 2026 |
| KURA | PRESS-RELEASE | bullish | 6/10 | Kura Oncology and Caspian Therapeutics announced preclinical data for KO-7246, a menin inhibitor for diabetes, showing β | Sep 29, 2026 |
| PHAR | PRESS-RELEASE | bearish | 6/10 | Pharming Group announced that CEO Fabrice Chouraqui has stepped down immediately by mutual agreement with the Board due | Sep 29, 2026 |
| SMMT | 8-K | bullish | 8/10 | Summit Therapeutics entered into a securities purchase agreement with AstraZeneca Holdings B.V. for a $2.0 billion priva | Sep 28, 2026 |
| HCM | 6-K | bullish | 6/10 | HUTCHMED announced the initiation of a global Phase Ia clinical trial for HMPL-A830, a first-in-class KRAS-EGFR antibody | Sep 28, 2026 |
| ETRA | SC 13G | neutral | 3/10 | Redmile Group, LLC and affiliated entities filed a Schedule 13G disclosing a passive 8.7% beneficial ownership stake in | Sep 28, 2026 |
| ETRA | SC 13G | neutral | 3/10 | LSP 7 Cooperatief U.A., a Netherlands-based venture capital firm (EQT Life Sciences), disclosed a 6.0% passive stake in | Sep 28, 2026 |
| HCM | PRESS-RELEASE | bullish | 7/10 | AstraZeneca submitted an NDA to the FDA for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in MET-overexpressed/ampl | Sep 28, 2026 |
| MRK | COURT-RULING | neutral | 1/10 | This is a routine procedural stipulation and order in the antitrust case Kaiser Foundation Health Plan v. Merck, grantin | Sep 28, 2026 |
| ABT | COURT-RULING | neutral | 2/10 | The District of Hawaii granted Abbott Laboratories' motion to transfer a False Claims Act retaliation lawsuit from Hawai | Sep 28, 2026 |
| ACOG | INSIDER-BUY | bullish | 5/10 | Opaleye Management Inc., a 10% owner of Alpha Cognition, purchased a total of 31,700 shares on the open market over two | Sep 28, 2026 |
| GOSS | SC 13D/A | bearish | 6/10 | D. E. Shaw's Amendment No. 4 to its Schedule 13D on Gossamer Bio reports that its Valence portfolio crossed below the 5% | Sep 28, 2026 |
| MEDP | SC 13D/A | neutral | 4/10 | August J. Troendle, CEO and founder of Medpace, filed Amendment No. 24 to his Schedule 13D, reporting a reduction in his | Sep 28, 2026 |
| RVMD | CLUSTER | neutral | 3/10 | Two insiders at Revolution Medicines sold a total of $645K in stock over a week. Director Elizabeth Anderson exercised a | Sep 28, 2026 |
| INBX | CLUSTER | bullish | 5/10 | Two INBX insiders, CEO Mark Lappe and Director Jon Faiz Kayyem, made open-market purchases totaling $829K over a week, w | Sep 28, 2026 |
| LFCR | SC 13D/A | bullish | 7/10 | Legion Partners Asset Management filed an amended Schedule 13D disclosing that Lifecore Biomedical entered into a defini | Sep 28, 2026 |
| AVXL | 8-K | neutral | 5/10 | Anavex Life Sciences held its 2026 Annual Meeting on September 24, 2026, where all six management director nominees were | Sep 28, 2026 |
| VKTX | 8-K | mixed | 6/10 | Viking Therapeutics issued $258.75M in 2.00% convertible senior notes due 2032, alongside a concurrent $275M common stoc | Sep 28, 2026 |
| EXOZ | DEFA14A | neutral | 3/10 | eXoZymes Inc. filed a DEFA14A (additional definitive proxy soliciting materials) on September 28, 2026, in connection wi | Sep 28, 2026 |
| EXOZ | DEF 14A | neutral | 3/10 | eXoZymes Inc. filed its definitive proxy statement for the 2026 annual meeting, seeking shareholder approval to elect si | Sep 28, 2026 |
| NAII | PRESS-RELEASE | bearish | 6/10 | NAI reported Q4 FY2026 net sales of $34.5M (+1.9% YoY) but a net loss of $13.5M ($2.23/diluted share), including a $10.4 | Sep 28, 2026 |